Baxter Reports Second-Quarter 2022 Results

Go back to Baxter Reports Second-Quarter 2022 Results

Stifel Reiterates Buy Rating on Baxter International (BAX)

July 28, 2022 9:57 AM EDT

Stifel analyst Rick Wise reiterated a Buy rating and $75.00 price target on Baxter International (NYSE: BAX)

The analyst comments "Macro challenges have been very much in evidence during initial 2Q22 MedTech reports. In Baxters 2Q, we are seeing the most significant negative... More

Evercore ISI on Baxter International (BAX) Guidance Update: 'we think the magnitude of the cut was a surprise'

July 28, 2022 9:55 AM EDT

Evercore ISI analyst Vijay Kumar reiterated an Outperform rating and $80.00 price target on Baxter International (NYSE: BAX).

The analyst comments "BAX reported organic rev growth of ~3%, which came in ~1% below Guide expectations. Total revs of $3.74 Bn came 3% below ST, and incl Fx impact of -500 bps (we are unsure... More

KeyBanc on Baxter International (BAX), Believes Investors are 'Dissappointed' With Q2 2022 Earnings Report and Guidance Update

July 28, 2022 9:53 AM EDT

KeyBanc analyst Matthew Mishan reiterated an Overweight rating and $87.00 price target on Baxter International (NYSE: BAX).

The analyst comments "We believe investors will view BAXs 2Q22 release and updated 2022 guidance as disappointing. 2Q revenue missed mostly on FX and weaker... More

Baxter (BAX) Reports In-Line Q2 EPS

July 28, 2022 7:25 AM EDT

Baxter (NYSE: BAX) reported Q2 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $3.75 billion versus the consensus estimate of $3.88 billion.

GUIDANCE:

Baxter sees FY2022 EPS of $3.60-$3.70, versus the consensus of $4.13.

For earnings history and earnings-related data on Baxter (BAX) click here.

... More